Meeting
2018 Gastrointestinal Cancers Symposium
PROX: Primary resistance to oxaliplatin containing regimen in the first line treatment of metastatic colorectal carcinoma—Retrospective analysis.
Authors
Larissa Machado
A.C. Camargo Cancer Center, São Paulo, Brazil
Larissa Machado , Tiago Felismino , Diogo De Brito Sales , Diogo Morbeck , Amanda Karani , Lara Azevedo Diniz , Ingrid Hariman Fonseca Cunha , Virgilio Souza , Maria Dirlei Begnami , Mariana Petaccia Macedo , Dirce Maria Carraro , Celso Lopes Mello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 855)
DOI
10.1200/JCO.2018.36.4_suppl.855
Abstract #
855
Poster Bd #
P7
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
The importance of sequence in rescheduling bevacizumab and chemotherapy administration in the first-line treatment of metastatic colorectal carcinoma (mCRC).
First Author: Leonidas Chelis
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOLFOXIRI ± molecular targeting agent (bevacizumab or panitumumab) for conversion from unresectable to resectable in the advanced/recurrent colorectal cancer.
First Author: Kodai Takemori
Poster
2015 Gastrointestinal Cancers Symposium
Randomized phase II studies comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab or cetuximab with FOLFOX or FOLFIRI.
First Author: Marc Van Den Eynde
Poster
2015 Gastrointestinal Cancers Symposium
Strategy for cStage4 colorectal cancer: Chemotherapy or resection of primary tumor?
First Author: Shigeyoshi Iwamoto